The Front Row at Scripps Research: lecture with Ben Cravatt, PhD

Scripps Research

Take a seat in the front row and listen as some of the world’s foremost scientists introduce you to innovative medicines and treatments.

10620 John Jay Hopkins Dr

<h3>Expanding the drug target universe with Ben Cravatt, PhD</h3><h3></h3>There are countless proteins that play critical roles in disease, yet they remain challenging to target with therapeutics. In this free Front Row lecture, professor Benjamin Cravatt will explain how his large-scale protein profiling research and innovative chemical technologies are helping identify novel drugs for therapeutic targets previously deemed ‘undruggable.’ Cravatt’s translational work, which is at the intersection of chemistry and biology, has also led to the formation of multiple local biotechnology companies that collectively employ hundreds of scientists who are developing first-in-class candidate medicines for diverse diseases range from cancer to neurological disorders.Learn more at <a href="https://www.frontrow.scripps.edu" title="https://www.frontrow.scripps.edu" target="_blank" data-msys-clicktrack="0" rel="nofollow noopener noreferrer">frontrow.scripps.edu</a>.About Scripps ResearchCommitted to unraveling the intricacies of the human body and translating our discoveries into tangible global impact, Scripps Research is consistently ranked among the most influential non-profit research institutes in the world. Throughout our 100-year history, our scientists have expanded the boundaries of scientific understanding and played a pivotal role in the development of over 15 FDA-approved medicines that have impacted the lives of countless individuals worldwide.The Front Row lecture series, now in its eighth season, offers an exclusive glimpse into groundbreaking scientific discoveries in action. Many of these breakthroughs are the result of years of tireless work—made possible by the support of our community.As we enter another century of science changing life at Scripps Research, our focus remains the same: fueling world-class fundamental and translational research to accelerate the development of medical advances for the benefit of human health.